Survival analysis of PLWHA undergoing combined antiretroviral therapy

Introduction: The survival time of human immunodeficiency virus (HIV)-infected individuals or patients with acquired immunodeficiency syndrome (AIDS) is influenced by multiple factors. Studying survival and influential factors after antiretroviral therapy (ART) contributes to improving treatment protocols, management strategies, and prognosis for people living with HIV/AIDS (PLWHA). Methods: This retrospective cohort study collected case data and follow-up records of PLWHA who received ART in Dazu District, Chongqing City, between 2007 and 2022. Cumulative survival rates were calculated using life tables. Survival curves were plotted using the Kaplan-Meier method. Uni-variable and multivariable Cox proportional hazards models analyzed factors influencing survival. Results: The study included 5,237 PLWHA receiving ART. Within the first year of ART initiation, 146 AIDS-related deaths occurred, accounting for 29.49% (146/495) of total deaths. Cumulative survival rates at 1, 5, 10, and 15 years were 0.97, 0.90, 0.85, and 0.79, respectively. During the observation period, male patients who received ART had a 1.89 times higher risk of death compared to females (aHR, 1.89; 95%; CI, 1.50-2.37). Patients aged ≥60 years had a 3.44-fold higher risk of death than those aged <30 years (aHR, 3.44; 95% CI, 1.22-9.67). Injection drug users (aHR, 4.95; 95% CI, 2.00-12.24) had a higher risk of death than those with heterosexual (aHR, 1.60; 95% CI, 0.69-3.72) and homosexual transmission. Patients with a baseline CD4+ T lymphocyte count <200 cells/μL (aHR, 8.02; 95% CI, 4.74-13.57) and between 200 and 349 cells/μL (aHR, 2.14; 95% CI, 1.26-3.64) had a higher risk of death than those with ≥350 cells/μL. Patients with ART initiation at WHO clinical stage IV had a 2.48-fold higher risk of death than those at stage I (aHR, 2.48; 95% CI, 1.17-5.23). Conclusion: The first year following ART initiation is critical in HIV/AIDS treatment, emphasizing the need for intensified follow-up and monitoring to facilitate successful immune system reconstruction. Older age, male sex, injection drug use, baseline CD4+ T lymphocyte count <200 cells/μL, and WHO clinical stage IV are associated with an increased risk of death. Tailored treatment and management strategies should be implemented for patient populations at higher risk of mortality and with a poorer prognosis

Antiretroviral therapy · Intensive care medicine · Viral load · HIV Research and Treatment · HIV/AIDS drug development and treatment · HIV/AIDS Research and Interventions · Medicine · Virology

• Survival time and influencing factors among people living with HIV in Guilin City, Guangxi, China

  Open Access•Yan Feng, Ge Li et al.•Frontiers in Public Health•2026

  Incluir item

• Facilitators and barriers to physical activity in middle-aged and older adult(s) HIV infected persons

  Open Access•Yali Zhou, Xutong Zheng et al.•Frontiers in Public Health•2026

  Incluir item

• Survival analysis and factors influencing survival time of adult HIV/Aids patients receiving antiretroviral therapy from 2012 to 2022 in Chongqing, China

  Open Access•Yao Zhi Huang, Yao Huang et al.•Frontiers in Public Health•2025

  Incluir item

• Adherence to Haart

  Open Access•Edward J Mills, Jean B Nachega et al.•PLoS Medicine•2006

  Incluir item

• Premature Age-Related Comorbidities Among HIV-Infected Persons Compared With the General Population

  Giovanni Guaraldi, Gabriella Orlando et al.•Clinical Infectious Diseases•2011

  Incluir item

• Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs

  Open Access•Frederick L Altice, Adeeba Kamarulzaman et al.•The Lancet•2010

  Incluir item

• Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy

  Open Access•Matthias Egger, Margaret May et al.•The Lancet•2002

  Incluir item

• Retracted

  Open Access•Riyaz Ahamed Shaik, Sharan K Holyachi et al.•Frontiers in Public Health•2023

  Incluir item

• Survival and risk factors associated with mortality in people living with HIV from 2005 to 2018 in Nanjing, China

  Open Access•Zhengping Zhu, Yuanyuan Xu et al.•Frontiers in Public Health•2022

  Incluir item

• Higher Risk of Mortality and Virologic Failure in HIV-Infected Patients With High Viral Load at Antiretroviral Therapy Initiation

  Open Access•Chao Zhou, Wei Zhang et al.•Frontiers in Public Health•2022

  Incluir item

• Challenges to meeting the HIV care needs of older adults in the rural South

  Open Access•K G Quinn, Steven A John et al.•SSM - Qualitative Research in…•2022

  Incluir item

• Determinants of survival in adult HIV patients on antiretroviral therapy in Oromiyaa, Ethiopia

  Open Access•Andinet Worku Alemu, Andinet Alemu et al.•Global Health Action•2010

  Incluir item

• Survival times of HIV/Aids in different Aids Diagnostic and Treatment Guidelines from 2006 to 2020 in Liuzhou, China

  Open Access•Susu Ke, Quan Fang et al.•BMC Public Health•2023

  Incluir item